Treatment with immunoglobulin replacement therapy is often used to boost antibody levels in an effort to reduce infection risk. "Many of the studies supporting the use of immunoglobulins to reduce ...

The SIGMA trial will assess Gamunex-C with standard medical treatment for patients with SID.

IgRT use in CLL patients has increased, yet it may not reduce serious infection rates and could correlate with higher infection incidences. The study's findings contrast with US research, highlighting ...

Treatment with immunoglobulin replacement therapy is often used to boost antibody levels in an effort to reduce infection risk. "Many of the studies supporting the use of immunoglobulins to reduce ...

One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX ® -C (immune globulin injection [human], 10% caprylate ...

Immunoglobulin replacement therapy in CLL patients does not reduce serious infection risk, despite increased usage over 14 years. The study found higher infection rates during immunoglobulin therapy ...

(WASHINGTON, July 31, 2025) — In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious ...

There is a push to reduce the demand for the plasma-derived therapy, as patients, physicians and governments worry about ...

Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...

Sepsis represents a dysregulated host response to infection, often leading to organ dysfunction and high mortality worldwide. Immunoglobulin therapy has emerged as a promising adjunct to standard ...

BHV-1300 reduced total IgG by up to 84% in a four-week Phase 1 study. The treatment was well-tolerated, with no serious adverse events reported. Get access to the leaderboards pointing to tomorrow’s ...